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Abstract
Background: It is well known that the use of the α-adrenergic receptor antagonists in the BPH
therapy may induce ejaculatory disorder. A review of clinical literature shows a greater incidence
of ejaculatory disorder during the use of tamsulosin compared with alfuzosin. Anejaculation has
been until now referred to retrograde ejaculation due to relaxation of prostatic and bladder neck
smooth muscle tone. In a recent researches was evaluated the effect of tamsulosin and alfuzosin on
rat vas deferent "in vitro", concluding that tamsulosin may "cause ejaculatory dysfunction by altering
the progression and emission of sperm". An abnormal increase of contraction would be the cause
of ejaculatory disorder. The aim of our paper is to compare human and rat vas deferens contractile
activity and to evaluate with a clinical study if tamsulosin causes retrograde ejaculation disorder.
Methods:  We have revaluated the human and rat vas deferens contractile activity in vitro
according to our experience and literature. We have also performed a clinical study on 10 patients
(48–72 y) affected by anejaculation. Post-coital urine was examined to search spermatozoa.
Results: Human and rat vas deferens activity is not comparable. Contractile activity induced by
norepinephrin after tamsulosin incubation in rat prostatic vas deferens strips is similar to the
contractile activity evoked by norepinephrin in human strips. Spermatozoa were found in post
coital urine of 6 patients.
Conclusion: In our opinion the treatment with tamsulosin may induce retrograde ejaculation but
not other ejaculatory disorder due to abnormal sperm progression.
Background
Alpha1-adrenoreceptor antagonists have been used for
years in the treatment of lower urinary tract symptoms
suggestive of benign prostatic hyperplasia (LUTS/BPH).
Over years, researches have identified different receptor
subpopulations and consequently more and more selec-
tive alpha antagonist drugs have been developed, acting
specifically on the lower urinary tract with lower effects on
the cardiovascular system.
Currently available α1-Adreno Receptor (α1-AR) antago-
nists show an excellent efficacy profile in improving both
the voiding (Qmax) and filling symptoms. The main dif-
ference among the α1 antagonists relates to the tolerability
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profile involving the cardiovascular (dizziness, arterial
hypotension) and genital (anejaculation) systems [6].
As for ejaculatory disorders, anejaculation had always
been thought to be caused by bladder neck relaxation.
Recent in vitro researches [2,4] on rats' deferent ducts have
suggested that the ejaculatory disorder would be second-
ary to anomalies in sperm progression due to the altera-
tion in the contractile mechanism of the vas deferens.
We carried out two studies: one 'in vitro' and one 'in vivo',
in order to verify this hypothesis.
Methods
The in vitro study was carried out on fragments of human
deferent duct taken from surgical portions (radical cystec-
tomy, radical prostatectomy, orchiectomy).
The experimental model used is the following: a thermo-
static bath, containing a segment of vas deferens fastened
to the bath bottom, is connected by means of an extensi-
ble wire to the lever arm of an isometric transducer, gen-
erating an electric pulse to the microdynamometer
recorder. The thermostatic bath maintains the tempera-
ture of the perfusion liquid at 37°C. The 'strip' of vas def-
erens is helicoidally cut so as to obtain a concentration
being the sum of the longitudinal and circular muscle
activity. The electric pulse transmitting the variations in
isometric tension reaches the microdynamometer
recorder: the sliding paper strip records the displacement
of the pen induced by the change in the preparation tone.
The abscissas axis indicates the sliding time corresponding
to 6 mm/min., and ordinates axis shows the tension
developed by the preparation, corresponding approxi-
mately to 1 cm/gram.
Fragments of vas deferens, taken from both epididymis and
prostate, were stimulated with noradrenaline (dose-
response curve) in order to evaluate the different mode of
contractile response.
We also carried out a clinical trial on 10 patients (age
range: 48–72 years) being treated with tamsulosin 0,4 mg
for obstructive micturition disorders suggestive of BPH or
bladder neck hypertonia and suffering from anejacula-
tion. Patients reported normal erectile and ejaculatory
activity, even if 7 out of 10 subjects had been noticing a
clear reduction in the ejaculate volume for some years.
Patients were asked to urinate 15 minutes after ejacula-
tion. Collected urines were centrifuged at 1500 RPM for 5
minutes. The sediment was evaluated by using a micro-
scope (40×) in order to detect the presence of sperm cells.
Results
The tonic component has prevailed over the phasic one in
the response of the epididymal portion [Fig. 1]. On the
contrary, the typical response of the prostatic deferent
duct has been characterized by an initial tonic-phasic
mixed activity, immediately followed by a phasic activity
marked by rapid strong "twitch-like" contractions. These
latter may suggest the presence of a mechanism recruiting
muscle cells, as if the vas deferens has a pace-maker action
which is morphologically quite similar to the "twitch"
that can be highlighted by electric stimulation [Fig. 2].
Following a dose-response stimulation with cumulative
logarithmic doses of noradrenaline, it has been possible
to observe that high doses of mediator markedly increase
the basic tone without altering the maximum contraction,
just as if the "twitch" represents the contraction that is
caused by the simultaneous excitation of all muscle cells
and cannot be consequently exceeded [Fig. 3].
As for the clinical trial, sperm cells were detected in urines
post-ejaculation in 6 out of 10 patients.
Discussion
Alpha1 adrenoreceptor antagonists are commonly used in
the treatment of LUTS/BPH. [4].
The presence of α-adrenergic receptors in the prostatic tis-
sue was demonstrated more than 30 years ago by Caine
[1]; over the latest years (1993), three α1-adrenergic recep-
tor subtypes were discovered: α1A, α1B, and α1D [5,14].
α1A receptor subtype may be responsible of the contrac-
tion of the prostate smooth muscles; it is expressed in the
prostate, trigone, bladder neck, seminal vesicles, deferent
duct and distal ureteral tract with a clear prevalence over
the other two subtypes. The α1D adrenoreceptor seems to
be mainly present in the bladder and spinal cord.
Response of an "epididymal" portion of the human vas defer- ens to a stimulation with noradrenaline (at the dose of 1.10– 6 gm/ml) Figure 1
Response of an "epididymal" portion of the human vas defer-
ens to a stimulation with noradrenaline (at the dose of 1.10–
6 gm/ml). The tonic component prevails over the phasic one.Journal of Translational Medicine 2006, 4:31 http://www.translational-medicine.com/content/4/1/31
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On the basis of this different distribution, recent
researches have suggested that α1A receptors mediate the
voiding symptoms, whereas α1D receptors are involved in
the development of the filling symptoms [13].
Several published clinical trials, have demonstrated the
efficacy of the α1-AR antagonists in the treatment of LUTS.
The meta-analysis – carried out by Djavan and Marberger
[6] in 1999, was recently updated with studies retrived
from a search in MEDLINE, BIOSIS and EMBASIS. This
updated meta-analysis has unquestionably demonstrated
the efficacy of the α1-AR antagonists in improving symp-
toms and Qmax, stressing again the key role of the alpha1
adrenoceptors in the development of LUTS [7].
Therefore, the impact of the α1-AR antagonists therapy on
the elderly subjects' quality of life is quite evident, also in
relation to the sexual function.
The ejaculatory function plays an important role in the
sexual activity. Several authors have shown a high preva-
lence of ejaculatory disorders in men with LUTS [8]. Ejac-
ulatory disorders have proven to be one of the most
relevant side-effect, apart from the adverse events related
to the cardiovascular system (dizziness, hypotension).
Ejaculatory disorders have been reported more often by
using the α1 antagonist tamsulosin [9].
In this regard, it seems particularly noteworthy to review
data generated from large-scale observational studies.
The "Multinational Survey of the Aging Male" (MSAM-7)
is a clinical trial carried out on 34,800 men (age: 50 to 80
years) in USA and in 6 European countries with the aim to
define the correlations between LUTS and sexual prob-
lems, by using questionnaires and validated symptoms
scales. For 12,815 men, results of the symptoms question-
naires were available.
Results
- 83% of men were still sexually active
- 46% of these subjects had noticed a reduced ejaculate
volume, while 5% reported the total absence of ejacula-
tion
- The prevalence of ejaculatory disorders significantly
increased with aging and severity of LUTS [10].
Another large-scale clinical trial (Asian Survey of aging
males) was carried out in 5 Asian countries on 1,155 men
aged between 50 and 80 years in order to establish the
prevalence of LUTS and sexual disorders, as well as their
correlation. The Authors observed that ejaculatory disor-
ders (68%) were slightly higher than erectile ones (63%)
and most men (52%) considered the ejaculatory dysfunc-
tion as the most bothersome problem [11].
Several hypotheses have been suggested about the correla-
tion between LUTS and ejaculatory disorders; however, no
definitive causal factor has been defined yet.
Following a dose-response stimulation with cumulative loga- rithmic doses of noradrenaline, it has been possible to  observe that high doses of mediator markedly increase the  basic tone without altering the maximum contraction (which  is manifest in rapid phasic contractions), as if the "twitch"  represents a contraction caused by the simultaneous excita- tion of all muscle cells and cannot be consequently exceeded Figure 3
Following a dose-response stimulation with cumulative loga-
rithmic doses of noradrenaline, it has been possible to 
observe that high doses of mediator markedly increase the 
basic tone without altering the maximum contraction (which 
is manifest in rapid phasic contractions), as if the "twitch" 
represents a contraction caused by the simultaneous excita-
tion of all muscle cells and cannot be consequently exceeded.
The typical response of the "prostatic" deferent duct has  been characterized by an initial tonic-phasic "mixed" activity,  immediately followed by a phasic activity marked by rapid  strong "twitch-like" contractions Figure 2
The typical response of the "prostatic" deferent duct has 
been characterized by an initial tonic-phasic "mixed" activity, 
immediately followed by a phasic activity marked by rapid 
strong "twitch-like" contractions. These latter may suggest 
the presence of a mechanism recruiting muscle cells, as if the 
vas deferens has a pace-maker action which is morphologi-
cally quite similar to the "twitch" that can be highlighted by 
electric stimulation.Journal of Translational Medicine 2006, 4:31 http://www.translational-medicine.com/content/4/1/31
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Some Authors have suggested that the increase in
noradrenergic activity, observed in men with bladder
emptying disorders, may interfere in the normal processes
of erection and ejaculation [10].
Other authors have supposed that physical changes asso-
ciated with BPH may mechanically alter the prostate and
compress ejaculatory ducts, thus causing a reduced ejected
volume and ejaculatory disorders [12].
Particularly noteworthy is a recent experimental work
(Tambaro  et al.), which has highlighted the different
action of tamsulosin versus alfuzosin on the contractile
activity of the deferent duct in rats, induced by noradren-
aline (NE). Tamsulosin may induce an abnormal increase
in the amplitude and frequency of contractions in the pro-
static portion of the rat vas deferens, which may probably
cause the ejaculatory dysfunction (anejaculation) due to
unsuccessful progression and ejection of sperm [4].
In this study, 'strips' of the rat vas deferens were dissected
at a distance of 1 cm from both prostatic and epididymal
ends. Then, they were stimulated with increasing concen-
trations of NE until obtaining the dose-response curve
with and without alfuzosin and tamsulosin.
NE has induced an initial rapid phasic contraction, fol-
lowed by a slow tonic one with several intermittent
'spikes'.
Tamsulosin pre-treatment has induced an abnormal
increase in intermittent spikes in both examined portions
of the vas deferens. The greatest increase in contraction
spikes has been observed in the prostatic tract (about +
550% in comparison with the control), whereas the tonic
and phasic components of the contraction have been sig-
nificantly reduced. Unlike tamsulosin, alfuzosin has not
induced any significant increase in contraction spikes,
even if it has shown a marked reduction in tonic and pha-
sic components of the contraction. Therefore, it seems the
response pattern is unaltered both in the epididymal and
prostatic tracts of the rat vas deferens.
A possible hypothesis explaining this phenomenon at the
prostatic level is the modulatory action of tamsulosin on
Ca++ channels and the release of ATP; on the other hand,
the inhibition of the response in the epididymal portion,
induced by the nerve stimulation, may be due to the
greater presence of α1D receptors, for which the affinity of
tamsulosin is definitely higher than the one of alfuzosin.
On the contrary, our in vitro study has highlighted a key
point, as also confirmed by other papers in literature [15]:
- the human deferent duct has a different contractile activ-
ity from that one of rats, as shown by Tambaro et al. In
particular, the prostatic portion of the deferent duct has
shown to respond to the stimulation with NE, with an
intense phasic activity similar to that one described as
'abnormal' after incubation with NE in the rat vas deferens.
This difference in terms of response can be interpreted in
different ways, considering the frequent inter-species var-
iables.
Furthermore, the need of using 1 cm. of isolated organ in
the experimental model to study the 'in vitro' contractile
activity has induced to evaluate the contractile response of
a portion of the deferent duct which corresponds to the
distal tenth of the human vas deferens. This latter also
includes a large portion of the intermediate tract in a rat
weighing 350 gr.
In that case, the contractile response cannot be considered
representative of the juxtaprostatic tract.
Conclusion
Based on the above-described data – on the evaluation of
the different (NE-induced) contractile response in the
human vas deferens, versus that one of rats, as well as the
presence of sperm cells in postcoital urine in 6 out of 10
patients – we think it is reasonable to conclude that tam-
sulosin-induced anejaculation is caused by a bladder neck
relaxation.
In fact, the low incidence of this phenomenon [6,7] is
well-justified by anatomical changes in the prostatic ure-
thra induced by BPH, whereas a direct effect on α1-
adrenoreceptors on the vas deferens may be more com-
mon and reproducible in most patients treated with tam-
sulosin.
Furthermore, it would be necessary to make a final obser-
vation: ejaculatory disorders are related to an aged popu-
lation suffering from LUTS/BPH – a condition that is
associated with a high proportion of sexual disorders, as
already mentioned.
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